BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lee HS, Lobbestael E, Vermeire S, Sabino J, Cleynen I. Inflammatory bowel disease and Parkinson's disease: common pathophysiological links. Gut 2021;70:408-17. [PMID: 33067333 DOI: 10.1136/gutjnl-2020-322429] [Cited by in Crossref: 18] [Cited by in F6Publishing: 31] [Article Influence: 18.0] [Reference Citation Analysis]
Number Citing Articles
1 Araújo B, Caridade-Silva R, Soares-Guedes C, Martins-Macedo J, Gomes ED, Monteiro S, Teixeira FG. Neuroinflammation and Parkinson's Disease-From Neurodegeneration to Therapeutic Opportunities. Cells 2022;11:2908. [PMID: 36139483 DOI: 10.3390/cells11182908] [Reference Citation Analysis]
2 Cui G, Li S, Ye H, Yang Y, Huang Q, Chu Y, Shi Z, Zhang X. Are neurodegenerative diseases associated with an increased risk of inflammatory bowel disease? A two-sample Mendelian randomization study. Front Immunol 2022;13:956005. [DOI: 10.3389/fimmu.2022.956005] [Reference Citation Analysis]
3 Boyd RJ, Avramopoulos D, Jantzie LL, McCallion AS. Neuroinflammation represents a common theme amongst genetic and environmental risk factors for Alzheimer and Parkinson diseases. J Neuroinflammation 2022;19:223. [PMID: 36076238 DOI: 10.1186/s12974-022-02584-x] [Reference Citation Analysis]
4 Zeng L, Yang T, Yang K, Yu G, Li J, Xiang W, Chen H. Curcumin and Curcuma longa Extract in the Treatment of 10 Types of Autoimmune Diseases: A Systematic Review and Meta-Analysis of 31 Randomized Controlled Trials. Front Immunol 2022;13:896476. [DOI: 10.3389/fimmu.2022.896476] [Reference Citation Analysis]
5 Chen SJ, Lin CH. Gut microenvironmental changes as a potential trigger in Parkinson's disease through the gut-brain axis. J Biomed Sci 2022;29:54. [PMID: 35897024 DOI: 10.1186/s12929-022-00839-6] [Reference Citation Analysis]
6 Sun X, Xue L, Wang Z, Xie A. Update to the Treatment of Parkinson's Disease Based on the Gut-Brain Axis Mechanism. Front Neurosci 2022;16:878239. [PMID: 35873830 DOI: 10.3389/fnins.2022.878239] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Hu M, Zhang X, Li J, Chen L, He X, Sui T. Fucosyltransferase 2: A Genetic Risk Factor for Intestinal Diseases. Front Microbiol 2022;13:940196. [DOI: 10.3389/fmicb.2022.940196] [Reference Citation Analysis]
8 Tan AH, Lim SY, Lang AE. The microbiome-gut-brain axis in Parkinson disease - from basic research to the clinic. Nat Rev Neurol 2022. [PMID: 35750883 DOI: 10.1038/s41582-022-00681-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
9 Yang R, Gao G, Yang H. The Pathological Mechanism Between the Intestine and Brain in the Early Stage of Parkinson's Disease. Front Aging Neurosci 2022;14:861035. [DOI: 10.3389/fnagi.2022.861035] [Reference Citation Analysis]
10 Zhu M, Liu X, Ye Y, Yan X, Cheng Y, Zhao L, Chen F, Ling Z. Gut Microbiota: A Novel Therapeutic Target for Parkinson’s Disease. Front Immunol 2022;13:937555. [DOI: 10.3389/fimmu.2022.937555] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
11 Zheng H, Qian X, Tian W, Cao L. Exploration of the Common Gene Characteristics and Molecular Mechanism of Parkinson's Disease and Crohn's Disease from Transcriptome Data. Brain Sci 2022;12:774. [PMID: 35741659 DOI: 10.3390/brainsci12060774] [Reference Citation Analysis]
12 Jackson A, Engen PA, Forsyth CB, Shaikh M, Naqib A, Wilber S, Frausto DM, Raeisi S, Green SJ, Bradaric BD, Persons AL, Voigt RM, Keshavarzian A. Intestinal Barrier Dysfunction in the Absence of Systemic Inflammation Fails to Exacerbate Motor Dysfunction and Brain Pathology in a Mouse Model of Parkinson's Disease. Front Neurol 2022;13:882628. [DOI: 10.3389/fneur.2022.882628] [Reference Citation Analysis]
13 Li D, Hong X, Chen T. Association Between Rheumatoid Arthritis and Risk of Parkinson's Disease: A Meta-Analysis and Systematic Review. Front Neurol 2022;13:885179. [DOI: 10.3389/fneur.2022.885179] [Reference Citation Analysis]
14 Zeng Y, Huang J, Tang X, Wang T, Chen S. The Impact of Triangle Hierarchical Management on Self-Management Behavior and Quality of Survival in Parkinson's Patients. Front Surg 2022;9:878477. [DOI: 10.3389/fsurg.2022.878477] [Reference Citation Analysis]
15 Tian Y, Zhang D, Nakamura M. Biological Clock and Inflammatory Bowel Disease Review: From the Standpoint of the Intestinal Barrier. Gastroenterology Research and Practice 2022;2022:1-11. [DOI: 10.1155/2022/2939921] [Reference Citation Analysis]
16 Padhi P, Worth C, Zenitsky G, Jin H, Sambamurti K, Anantharam V, Kanthasamy A, Kanthasamy AG. Mechanistic Insights Into Gut Microbiome Dysbiosis-Mediated Neuroimmune Dysregulation and Protein Misfolding and Clearance in the Pathogenesis of Chronic Neurodegenerative Disorders. Front Neurosci 2022;16:836605. [DOI: 10.3389/fnins.2022.836605] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
17 McGrath T, Baskerville R, Rogero M, Castell L. Emerging Evidence for the Widespread Role of Glutamatergic Dysfunction in Neuropsychiatric Diseases. Nutrients 2022;14:917. [PMID: 35267893 DOI: 10.3390/nu14050917] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
18 Folke J, Ferreira N, Brudek T, Borghammer P, Van Den Berge NVD. Passive Immunization in Alpha-Synuclein Preclinical Animal Models. Biomolecules 2022;12:168. [DOI: 10.3390/biom12020168] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
19 Iannotta L, Greggio E. LRRK2 signaling in neurodegeneration: two decades of progress. Essays Biochem 2021:EBC20210013. [PMID: 34897411 DOI: 10.1042/EBC20210013] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Li Y, Chen Y, Jiang L, Zhang J, Tong X, Chen D, Le W. Intestinal Inflammation and Parkinson's Disease. Aging Dis 2021;12:2052-68. [PMID: 34881085 DOI: 10.14336/AD.2021.0418] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
21 Kurnik-Łucka M, Pasieka P, Łączak P, Wojnarski M, Jurczyk M, Gil K. Gastrointestinal Dopamine in Inflammatory Bowel Diseases: A Systematic Review. Int J Mol Sci 2021;22:12932. [PMID: 34884737 DOI: 10.3390/ijms222312932] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
22 Gorecki AM, Anyaegbu CC, Anderton RS. TLR2 and TLR4 in Parkinson's disease pathogenesis: the environment takes a toll on the gut. Transl Neurodegener 2021;10:47. [PMID: 34814947 DOI: 10.1186/s40035-021-00271-0] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
23 Gerasimova-Meigal L, Meigal A, Sireneva N, Saenko I. Autonomic Function in Parkinson's Disease Subjects Across Repeated Short-Term Dry Immersion: Evidence From Linear and Non-linear HRV Parameters. Front Physiol 2021;12:712365. [PMID: 34690794 DOI: 10.3389/fphys.2021.712365] [Reference Citation Analysis]
24 Fousekis FS, Katsanos AH, Kourtis G, Saridi M, Albani E, Katsanos KH, Christodoulou DK. Inflammatory Bowel Disease and Patients With Mental Disorders: What Do We Know? J Clin Med Res 2021;13:466-73. [PMID: 34691320 DOI: 10.14740/jocmr4593] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Cocoros NM, Svensson E, Szépligeti SK, Vestergaard SV, Szentkúti P, Thomsen RW, Borghammer P, Sørensen HT, Henderson VW. Long-term Risk of Parkinson Disease Following Influenza and Other Infections. JAMA Neurol 2021. [PMID: 34694344 DOI: 10.1001/jamaneurol.2021.3895] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
26 Zhang K, Zhu S, Li J, Jiang T, Feng L, Pei J, Wang G, Ouyang L, Liu B. Targeting autophagy using small-molecule compounds to improve potential therapy of Parkinson's disease. Acta Pharm Sin B 2021;11:3015-34. [PMID: 34729301 DOI: 10.1016/j.apsb.2021.02.016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
27 Derkinderen P, Noble W, Neunlist M, Rolli-Derkinderen M. Upregulation of enteric alpha-synuclein as a possible link between inflammatory bowel disease and Parkinson's disease. Gut 2021;70:2010-2. [PMID: 33203725 DOI: 10.1136/gutjnl-2020-323482] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
28 Zhou C, Zhou H, Zhang F, Hao L, Guo J. Active Ingredients and Potential Mechanisms of the Gan Jiang-Huang Qin-Huang Lian-Ren Shen Decoction against Ulcerative Colitis: A Network Pharmacology and Molecular Docking-Based Study. Evid Based Complement Alternat Med 2021;2021:1925718. [PMID: 34539797 DOI: 10.1155/2021/1925718] [Reference Citation Analysis]
29 Lei Q, Wu T, Wu J, Hu X, Guan Y, Wang Y, Yan J, Shi G. Roles of α‑synuclein in gastrointestinal microbiome dysbiosis‑related Parkinson's disease progression (Review). Mol Med Rep 2021;24:734. [PMID: 34414447 DOI: 10.3892/mmr.2021.12374] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
30 Yamamoto S, Saito M, Tamura A, Prawisuda D, Mizutani T, Yotsuyanagi H. The human microbiome and COVID-19: A systematic review. PLoS One 2021;16:e0253293. [PMID: 34161373 DOI: 10.1371/journal.pone.0253293] [Cited by in Crossref: 4] [Cited by in F6Publishing: 36] [Article Influence: 4.0] [Reference Citation Analysis]
31 Dumitrescu L, Marta D, Dănău A, Lefter A, Tulbă D, Cozma L, Manole E, Gherghiceanu M, Ceafalan LC, Popescu BO. Serum and Fecal Markers of Intestinal Inflammation and Intestinal Barrier Permeability Are Elevated in Parkinson's Disease. Front Neurosci 2021;15:689723. [PMID: 34220443 DOI: 10.3389/fnins.2021.689723] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
32 Wei Y, Chang L, Hashimoto K. Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor. Mol Psychiatry 2021. [PMID: 33963284 DOI: 10.1038/s41380-021-01121-1] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 39.0] [Reference Citation Analysis]